We deduce that the combination treatment with CuB and an ERK inhibitor against pancreatic cancer may be more effective than single drug treatment due to complementary effects on STAT3, ERK and EGFR activities. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.